Vicore Pharma Holding AB (OSTO:VICO) Cyclically Adjusted FCF per Share: kr-2.48 (As of Mar. 2026)


OSTO:VICO Vicore Pharma Holding AB OSTO:VICO
29 GF Score
Price kr12.76
! 5 Warning Signs
View Full Analysis

What is Vicore Pharma Holding AB Cyclically Adjusted FCF per Share?

Vicore Pharma Holding AB OSTO:VICO -0.62% 29 Cyclically Adjusted FCF per Share is kr-2.48 as of Mar. 2026. GuruFocus rates OSTO:VICO with a GF Score™ of 29/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Vicore Pharma Holding AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.418. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-2.48 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-11), Vicore Pharma Holding AB's current stock price is kr12.76. Vicore Pharma Holding AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-2.48. Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF of today is .


Vicore Pharma Holding AB  (OSTO:VICO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Vicore Pharma Holding AB Cyclically Adjusted FCF per Share Related Terms


Vicore Pharma Holding AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Vicore Pharma Holding AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vicore Pharma Holding AB Cyclically Adjusted FCF per Share Chart

Vicore Pharma Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -2.59 -2.50

Vicore Pharma Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.56 -2.55 -2.53 -2.50 -2.48

OSTO:VICO vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vicore Pharma Holding AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Vicore Pharma Holding AB's Cyclically Adjusted Price-to-FCF falls into.


OSTO:VICO
29GF Score
Vicore Pharma Holding AB OSTO:VICO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vicore Pharma Holding AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vicore Pharma Holding AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.418/133.5600*133.5600
=-0.418

Current CPI (Mar. 2026) = 133.5600.

Vicore Pharma Holding AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.372 101.019 -0.492
201609 -0.195 101.138 -0.258
201612 -0.321 102.022 -0.420
201703 -0.331 102.022 -0.433
201706 -0.473 102.752 -0.615
201709 -0.475 103.279 -0.614
201712 -0.287 103.793 -0.369
201803 -0.421 103.962 -0.541
201806 0.238 104.875 0.303
201809 -0.200 105.679 -0.253
201812 -0.755 105.912 -0.952
201903 -0.444 105.886 -0.560
201906 -0.518 106.742 -0.648
201909 -0.488 107.214 -0.608
201912 -0.525 107.766 -0.651
202003 -0.565 106.563 -0.708
202006 -0.498 107.498 -0.619
202009 -0.450 107.635 -0.558
202012 -0.629 108.296 -0.776
202103 -0.734 108.360 -0.905
202106 -1.001 108.928 -1.227
202109 -0.927 110.338 -1.122
202112 -1.020 112.486 -1.211
202203 -0.971 114.825 -1.129
202206 -0.871 118.384 -0.983
202209 -0.904 122.296 -0.987
202212 -1.328 126.365 -1.404
202303 -0.924 127.042 -0.971
202306 -0.821 129.407 -0.847
202309 -0.316 130.224 -0.324
202312 -0.604 131.912 -0.612
202403 0.207 132.205 0.209
202406 -0.444 132.716 -0.447
202409 -0.781 132.304 -0.788
202412 -0.246 132.987 -0.247
202503 -0.367 132.825 -0.369
202506 -0.454 133.699 -0.454
202509 -0.428 133.480 -0.428
202512 -0.319 133.390 -0.319
202603 -0.418 133.560 -0.418

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-2.48 mean?
Vicore Pharma Holding AB (OSTO:VICO) has a Cyclically Adjusted FCF per Share of kr-2.48 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vicore Pharma Holding AB and its competitors.
Is Vicore Pharma Holding AB's Cyclically Adjusted FCF per Share too high?
Vicore Pharma Holding AB's current Cyclically Adjusted FCF per Share is kr-2.48. Overall, Vicore Pharma Holding AB has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Vicore Pharma Holding AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Vicore Pharma Holding AB's Cyclically Adjusted FCF per Share of kr-2.48 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Vicore Pharma Holding AB and its competitors. Vicore Pharma Holding AB's current Cyclically Adjusted FCF per Share is kr-2.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vicore Pharma Holding AB stock overvalued right now?
Vicore Pharma Holding AB (OSTO:VICO) has a current Cyclically Adjusted FCF per Share of kr-2.48. The current Cyclically Adjusted FCF per Share is kr-2.48. Vicore Pharma Holding AB's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Vicore Pharma Holding AB (OSTO:VICO), the current Cyclically Adjusted FCF per Share is kr-2.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vicore Pharma Holding AB Business Description

Other Exchanges 6Y4:Germany
Address Kornhamnstorg 53, Stockholm, SWE, 111 27
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.
29GF Score

Get the complete analysis for OSTO:VICO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.76
Price